I think the part that's understood is "will continue to make its way through clinical trials." In other words, many more years of testing to see if it really works.
I agree that is disappointing that a journal as highly regarded makes such mistakes, but when I was reviewing research we found plenty of mistakes in such journals. The good news is that AVXL was mentioned.
Falconer: I find it interesting that Nature Magazine, in highlighting various scientific breakthroughs to keep an eye on in 2023, mentioned only two in the “hot” field of Alzheimer’s disease — Biogen’s Lecanemab and Anavex’s Blaracmesine.
Could it be that the expected Peer Review is under review at Nature?